Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy

Brachytherapy

Volumn 12, Issue 3, 2013, Pages 204-209

  Pugh, Thomas J ^a   Frank, Steven J ^a   Achim, Mary ^a   Kuban, Deborah A ^a   Lee, Andrew K ^a   Hoffman, Karen E ^a   McGuire, Sean E ^a   Swanson, David A ^a   Kudchadker, Rajat ^a   Davis, John W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Brachytherapy; Extraprostatic extension; Magnetic resonance imaging; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; DIAGNOSTIC VALUE; ENDORECTAL MAGNETIC RESONANCE IMAGING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR VOLUME;

ADULT; AGED; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATIC NEOPLASMS; RECTUM; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84876723894     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.12.013     Document Type: Article

References (39)

1. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008, 179(Suppl. 5):S20-S24.
2. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002, 12:81-94.
3. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277:1445-1451.
4. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
5. Brachman D.G., Thomas T., Hilbe J., et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 2000, 48:111-117.
6. Kwok Y., DiBiase S.J., Amin P.P., et al. Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 2002, 53:588-594.
7. Butzbach D., Waterman F.M., Dicker A.P. Can extraprostatic extension be treated by prostate brachytherapy? An analysis based on postimplant dosimetry. Int J Radiat Oncol Biol Phys 2001, 51:1196-1199.
8. Blasko J.C., Grimm P.D., Sylvester J.E., et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000, 57:273-278.
9. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 61:32-43.
10. Augustin H., Isbarn H., Auprich M., et al. Head to head comparison of three generations of Partin tables to predict final pathological stage in clinically localised prostate cancer. Eur J Cancer 2010, 46:2235-2241.
11. Fütterer J.J., Engelbrecht M.R., Jager G.J., et al. Prostate cancer: Comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 2007, 17:1055-1065.
12. D'Amico A.V., Schnall M., Whittington R., et al. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology 1998, 51:449-454.
13. Bloch B.N., Furman-Haran E., Helbich T.H., et al. Prostate cancer: Accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging-initial results. Radiology 2007, 245:176-185.
14. Park S.Y., Kim J.J., Kim T.H., et al. The role of endorectal magnetic resonance imaging in predicting extraprostatic extension and seminal vesicle invasion in clinically localized prostate cancer. Korean J Urol 2010, 51:308-312.
15. Wang L., Zhang J., Schwartz L.H., et al. Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI. AJR Am J Roentgenol 2007, 188:99-104.
16. Zhang J., Hricak H., Shukla-Dave A., et al. Clinical stage T1c prostate cancer: Evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology 2009, 253:425-434.
17. Chen M.E., Johnston D., Reyes A.O., et al. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volumes. Am J Surg Path 2003, 27:1291-1301.
18. Chen M.E., Johnston D.A., Tang K., et al. Detailed mapping of prostate carcinoma foci: Biopsy strategy implications. Cancer 2000, 89:1800-1809.
19. Frank S.J., Arterbery V.E., Hsu I.J., et al. American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. Brachytherapy 2011, 10:357-362.
20. Frank S., Grimm P., Sylvester J., et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy 2007, 6:2-8.
21. Ruprecht O., Weisser P., Bodelle B., et al. MRI of the prostate: Interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol 2011, 81:456-460.
22. Augustin H., Fritz G.A., Ehammer T., et al. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables. Acta Radiol 2009, 50:562-569.
23. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol 1996, 14:1770-1777.
24. Brajtbord J.S., Lavery H.J., Nabizada-Pace F., et al. Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer. BJU Int 2011, 107:1419-1424.
25. Fuchsjäger M.H., Pucar D., Zelefsky M.J., et al. Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI. Int J Radiat Oncol Biol Phys 2010, 78:743-750.
26. Nishimoto K., Nakashima J., Hashiguchi A., et al. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Int J Urol 2008, 15:520-523.
27. D'Amico A.V., Whittington R., Schnall M., et al. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer. Cancer 1995, 75:2368-2372.
28. Jager G.J., Ruijter E.T., van de Kaa C.A., et al. Local staging of prostate cancer with endorectal MR imaging: Correlation with histopathology. AJR Am J Roentgenol 1996, 166:845-852.
29. Heidenreich A. Consensus criteria for the use of magnetic resonance imaging in the diagnosis and staging of prostate cancer: Not ready for routine use. Eur Urol 2011, 59:495-497.
30. Wang L., Hricak H., Kattan M.W., et al. Prediction of organ-confined prostate cancer: Incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006, 238:597-603.
31. Wang L., Hricak H., Kattan M.W., et al. Prediction of seminal vesicle invasion in prostate cancer: Incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 2007, 242:182-188.
32. Chao K.K., Goldstein N.S., Yan D., et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: Should the clinical target volume be expanded posterolaterally to account for microscopic extension?. Int J Radiat Oncol Biol Phys 2006, 65:999-1007.
33. Davis B.J., Pisansky T.M., Wilson T.M., et al. The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy. Cancer 1999, 85:2630-2637.
34. Sohayda C., Kupelian P.A., Levin H.S., et al. Extent of extracapsular extension in localized prostate cancer. Urology 2000, 55:382-386.
35. The B.S., Bastasch M.D., Mai W.Y., et al. Predictors of extracapsular extension and its radial distance in prostate cancer: Implication for prostate IMRT, brachytherapy, and surgery. Cancer J 2003, 9:454-460.
36. Schwartz D.J., Sengupta S., Hillman D.W., et al. Prediction of radial distance of extraprostatic extension from pretherapy factors. Int J Radiat Oncol Biol Phys 2007, 69:411-418.
37. Crook J., Patil N., Ma C., et al. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 2010, 77:1079-1084.
38. Satake N., Ohori M., Yu C., et al. Development and internal validation of a nomogram predicting extracapsular extension in radical prostatectomy specimens. Int J Urol 2010, 17:267-272.
39. Engelbrecht M.R., Jager G.J., Laheij R.J., et al. Local staging of prostate cancer using magnetic resonance imaging: A meta-analysis. Eur Radiol 2002, 12:2294-2302.